Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
| Revenue (TTM) | $46.88M |
| Gross Profit (TTM) | $31.91M |
| EBITDA | $-163.39M |
| Operating Margin | -293.70% |
| Return on Equity | 33.10% |
| Return on Assets | -32.80% |
| Revenue/Share (TTM) | $0.38 |
| Book Value | $0.51 |
| Price-to-Book | 2.85 |
| Price-to-Sales (TTM) | 5.49 |
| EV/Revenue | 2.061 |
| EV/EBITDA | 1.28 |
| Quarterly Earnings Growth (YoY) | -75.50% |
| Quarterly Revenue Growth (YoY) | 62.00% |
| Shares Outstanding | $154.25M |
| Float | $132.53M |
| % Insiders | 18.66% |
| % Institutions | 38.65% |
Volatility is currently expanding
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – – First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor –
Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipeline despite recent market negativity. Key catalysts include mid-2026 data readouts for casdozokitug in HCC and ongoing pivotal JUPITER-02 trial for toripalimab in nasopharyngeal carcinoma. CHRS's liquidity covers 2–3 quarters at current cash burn; further financing may be needed before pivotal clinical milestones.
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
